Organon & Co. (NYSE: OGN), a firm with a strong focus on women’s health that split from Merck, Sharp & Dohme (MSD, NYSE: MRK) in mid-2021, announced at the 5th China International Import Expo (CIIE) the signing of a memorandum of understanding (MOU) with the National Health Commission (NHC). The long-term partnership aims to leverage the respective resource advantages of government, enterprise, academia, and medicine to empower primary general practitioners (GPs) in China.
Partnership with National Health Commission
The collaboration with the NHC is designed to enhance the capabilities of primary care physicians in China by integrating resources from multiple sectors. This initiative underscores Organon’s commitment to improving healthcare outcomes and supporting the professional development of GPs in the country.
Partnership with Baidu Health
On the same day, Organon also announced a partnership with Baidu Health, the one-stop health management platform of China-based Internet giant Baidu. The collaboration will utilize Organon’s medical science expertise and Baidu Health’s technological advantages to explore precision digital disease and health education services, focusing on common chronic diseases. This strategic move aims to improve patient outcomes through innovative digital health solutions.
Future Prospects
These partnerships highlight Organon’s ongoing efforts to advance women’s health and digital health initiatives in China. By working with key stakeholders, Organon aims to enhance healthcare delivery and improve access to quality medical services for patients.-Fineline Info & Tech
